Difference between revisions of "Idarucizumab (Praxbind)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "[https://online.lexi.com/lco/action/login UpToDate Lexidrug]") |
||
(One intermediate revision by one other user not shown) | |||
Line 4: | Line 4: | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [ | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
Line 17: | Line 17: | ||
*2016-09-28: New approval for the reversal of anticoagulant effect of dabigatran under the following situations: life-threatening or uncontrolled bleeding; and when performing emergency surgery or procedures in which serious bleeding is expected. | *2016-09-28: New approval for the reversal of anticoagulant effect of dabigatran under the following situations: life-threatening or uncontrolled bleeding; and when performing emergency surgery or procedures in which serious bleeding is expected. | ||
==Also known as== | ==Also known as== | ||
− | *'''Code name:''' BI 655075 | + | *'''Code name:''' BI-655075 |
*'''Brand name:''' Praxbind | *'''Brand name:''' Praxbind | ||
Latest revision as of 01:26, 27 June 2024
General information
Class/mechanism: Monoclonal antibody fragment (Fab) that binds to Dabigatran (Pradaxa) and its metabolites with higher affinity than dabigatran binds to thrombin, which neutralizes the anticoagulant effect of dabigatran.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2015-10-16: Approved in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.
History of changes in PMDA indication
- 2016-09-28: New approval for the reversal of anticoagulant effect of dabigatran under the following situations: life-threatening or uncontrolled bleeding; and when performing emergency surgery or procedures in which serious bleeding is expected.
Also known as
- Code name: BI-655075
- Brand name: Praxbind